



25 April 2023

RE: MERA Study Closure

A Phase 1, Blinded, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of BIIB132 Administered Intrathecally to Adults With Spinocerebellar Ataxia type 3

Dear National Ataxia Foundation:

Biogen has made the difficult decision to stop the MERA study for Spinocerebellar Ataxia type 3. The decision was made after careful assessment of the nonclinical safety data, clinical pharmacodynamic data, and future development of BIIB132.

This is not the outcome we had hoped for and we acknowledge that this news may be disappointing to SCA3 patients and the entire ataxia community. We greatly appreciate the dedication and support by patients, their families, and patient advocacy. Biogen remains committed to ataxia research.

Sincerely,

A handwritten signature in blue ink that reads "Rosalind S. Chuang".

Rosalind Chuang, MD
Medical Director
Movement Disorders, Neurodegeneration Development Unit